Lannett Co (NYSE: LCI) has recently received a number of price target changes and ratings updates:

  • 8/2/2017 – Lannett Co was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/24/2017 – Lannett Co was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/18/2017 – Lannett Co was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $25.00 price target on the stock. According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
  • 7/17/2017 – Lannett Co had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $23.00 price target on the stock, up previously from $22.00.
  • 7/11/2017 – Lannett Co was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies. “
  • 6/8/2017 – Lannett Co had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..

Lannett Co Inc (NYSE LCI) traded up 1.5431% during trading on Monday, reaching $16.9577. 242,144 shares of the company were exchanged. The company’s 50-day moving average price is $20.49 and its 200-day moving average price is $21.48. The stock’s market capitalization is $631.34 million. Lannett Co Inc has a 1-year low of $16.38 and a 1-year high of $39.99.

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.